Akari Therapeutics (AKTX) Registration Filing summary

Company overview and business model

• Focuses on developing next-generation antibody-drug conjugates (ADCs) with novel proprietary cancer-killing payloads targeting solid tumors, aiming to improve efficacy and safety over existing ADCs.

• Lead product candidate, AKTX-101, is a preclinical Trop2-targeting ADC for various solid tumors; pipeline expanded through the acquisition of Peak Bio.

• Suspended internal development of legacy programs to prioritize the ADC platform and seeks external partners for non-core assets.

Financial performance and metrics

• No commercial products or product revenue to date; operations have focused on R&D and capital raising.

• Pro forma combined net loss for 2024 was $19.5 million, reflecting significant R&D and merger-related costs.

• March 2025 private placement raised approximately $6 million in net proceeds.

Use of proceeds and capital allocation

• Proceeds from securities sales will be used for general corporate purposes, with significant discretion in allocation.